摘要
目的 :探讨和络舒肝胶囊对肝炎后肝硬化患者的临床疗效。方法 :肝炎后肝硬化患者 85例 ,随机分成治疗组 45例 ,对照组 40例。对照组采用综合治疗 ,治疗组在综合治疗的基础上 ,加用和络舒肝胶囊 5粒 ,tid ,po ,3个月为 1个疗程。结果 :治疗组有效率 91.1% ,对照组有效率 5 5 .0 % ,治疗组在临床症状、体征及肝功能的改善方面均优于对照组 ,两组差异均有极显著性 (均P <0 .0 1) ,未见严重的药物不良反应。结论 :和络舒肝胶囊治疗肝炎后肝硬化疗效明显 。
Objective:To probe into the clinical therapeutic effectiveness of Heluoshugan capsules in the treatment of posthepatitic cirrhosis. Methods:85 patients with posthepatitic cirrhosis were randomly divided into two groups,the treatment group( n =45) and the control group( n =40). Patients of the control group were subjected to combined liver protection therapy. On the basis of the combined therepy, patients of the treatment group were given each 5 Heluoshugan capsules, t.i.d., PO. The course of the treatment lasted 3 months. Results:The effective rates were 91.1% and 55.0% in the treatment group and control group, respectively( P < 0.01 ). The improvement in clinical symptoms and signs as well as the amelioration of the liver function were far more pronounced in the treatment group than in the control group( P <0.01). No serious adverse reactions were encountered. Conclusion: Heluoshugan capsules were shown to have a fairly good and definite therapeutic effect in the treatment of posthepatitic cirrhosis and the authors suggest to spread the clinical application of the drug.
出处
《医药导报》
CAS
2003年第4期238-239,共2页
Herald of Medicine
